Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

References

• Massagué J. TGFbeta in Cancer. Cell 2008; 134:215 - 30; http://dx.doi.org/10.1016/j.cell.2008.07.001; PMID: 18662538
   PubMed Web of Science ®Google Scholar
• Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol 2009; 5:259 - 71; http://dx.doi.org/10.2217/14796694.5.2.259; PMID: 19284383
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012; 11:790 - 811; http://dx.doi.org/10.1038/nrd3810; PMID: 23000686
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29:117 - 29; http://dx.doi.org/10.1038/ng1001-117; PMID: 11586292
   PubMed Web of Science ®Google Scholar
• Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10:554 - 67; http://dx.doi.org/10.1038/nri2808; PMID: 20616810
   PubMed Web of Science ®Google Scholar
• Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008; 134:392 - 404; http://dx.doi.org/10.1016/j.cell.2008.07.025; PMID: 18692464
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 2010; 147:781 - 92; http://dx.doi.org/10.1093/jb/mvq043; PMID: 20410014
   PubMed Web of Science ®Google Scholar
• Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 2012; 4:29 - 37; http://dx.doi.org/10.1093/jmcb/mjr033; PMID: 22158907
   PubMed Web of Science ®Google Scholar
• Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136:3916 - 20; PMID: 2871107
   PubMed Web of Science ®Google Scholar
• Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol 1995; 155:1066 - 73; PMID: 7636180
   PubMed Web of Science ®Google Scholar
• Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003; 100:4120 - 5; http://dx.doi.org/10.1073/pnas.0730640100; PMID: 12646700
   PubMed Web of Science ®Google Scholar
• Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172:7335 - 40; PMID: 15187109
   PubMed Web of Science ®Google Scholar
• Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, Coligan JE. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood 2011; 118:3019 - 27; http://dx.doi.org/10.1182/blood-2011-04-346825; PMID: 21816829
   PubMed Web of Science ®Google Scholar
• Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 2011; 6:e22842; http://dx.doi.org/10.1371/journal.pone.0022842; PMID: 21909397
   PubMed Web of Science ®Google Scholar
• Biswas S, Criswell TL, Wang SE, Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin Cancer Res 2006; 12:4142 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-06-0952; PMID: 16857784
   PubMed Web of Science ®Google Scholar
• Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012; 8:964 - 78; http://dx.doi.org/10.7150/ijbs.4564; PMID: 22811618
   PubMed Web of Science ®Google Scholar
• Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011; 79:1236 - 43; http://dx.doi.org/10.1038/ki.2011.33; PMID: 21368745
   PubMed Web of Science ®Google Scholar
• Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-β in cancer patients. Curr Pharm Biotechnol 2011; 12:2176 - 89; http://dx.doi.org/10.2174/138920111798808392; PMID: 21619535
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Cheung HK, Ling L, DeLong P, Kaiser LR, Albelda SM. Soluble Type II Transforming Growth Factor-β Receptor inhibits both small and large established murine malignant mesothelioma tumor growth by augmenting host anti-tumor Immunity. Clin Ca Res 2004; 10:5907 - 18; http://dx.doi.org/10.1158/1078-0432.CCR-03-0611
   PubMed Web of Science ®Google Scholar
• Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995; 12:455 - 60; http://dx.doi.org/10.1165/ajrcmb.12.5.7742009; PMID: 7742009
   PubMed Web of Science ®Google Scholar
• Marzo AL, Fitzpatrick DR, Robinson BWS, Scott B. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.. Cancer Res 1997; 57:3200 - 7; PMID: 9242450
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kim S, Cheung HK, Corbley M, Zhang X, Sun L, Shan F, Singh J, et al. A novel small molecule inhibitor of TGF-beta type I Receptor Kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents the extent of tumor recurrence after surgical resection. Cancer Res 2007; 67:2351 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-06-2389; PMID: 17332368
   PubMed Web of Science ®Google Scholar
• Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10:266 - 83; http://dx.doi.org/10.1111/j.1440-1843.2005.00714.x; PMID: 15955137
   PubMed Web of Science ®Google Scholar
• Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995; 12:455 - 60; http://dx.doi.org/10.1165/ajrcmb.12.5.7742009; PMID: 7742009
   PubMed Web of Science ®Google Scholar
• Kuwahara M, Takeda M, Takeuchi Y, Kuwahara M, Harada T, Maita K. Transforming growth factor β production by spontaneous malignant mesothelioma cell lines derived from Fisher 344 rats. Virchows Arch 2001; 438:492 - 7; http://dx.doi.org/10.1007/s004280000363; PMID: 11407478
   PubMed Web of Science ®Google Scholar
• Gerwin BI, Lechner JF, Reddel RR, Roberts AB, Robbins KC, Gabrielson EW, Harris CC. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 1987; 47:6180 - 4; PMID: 3479241
   PubMed Web of Science ®Google Scholar
• Lauber B, Leuthold M, Schmitter D, Cano-Santos J, Waibel R, Stahel RA. An autocrine mitogenic activity produced by a pleural human mesothelioma cell line. Int J Cancer 1992; 50:943 - 50; http://dx.doi.org/10.1002/ijc.2910500621; PMID: 1555893
   PubMed Web of Science ®Google Scholar
• Kumar-Singh S, Weyler J, Martin MJH, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999; 189:72 - 8; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; PMID: 10451491
   PubMed Web of Science ®Google Scholar
• Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Bégin R, Rom WN. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 1997; 105:Suppl 5 1197 - 203; PMID: 9400723
   PubMed Web of Science ®Google Scholar
• DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005; 4:342 - 6; http://dx.doi.org/10.4161/cbt.4.3.1644; PMID: 15846066
   PubMed Web of Science ®Google Scholar
• Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227 - 58; http://dx.doi.org/10.1146/annurev-immunol-020711-075005; PMID: 23516982
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 2010; 12:7 - 13; http://dx.doi.org/10.1093/neuonc/nop009; PMID: 20150362
   PubMed Web of Science ®Google Scholar
• Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012; 119:5688 - 96; http://dx.doi.org/10.1182/blood-2011-10-386482; PMID: 22555974
   PubMed Web of Science ®Google Scholar
• Morris JC, Shapiro AR, Tan DP et al. Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 9028).
   Google Scholar
• Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, Akhurst RJ. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86:531 - 42; http://dx.doi.org/10.1016/S0092-8674(00)80127-0; PMID: 8752208
   PubMed Web of Science ®Google Scholar
• Kaira K, Dobashi K, Yanagitani N, Sunaga N, Shimizu Y, Hisada T, Ishizuka T, Nakajima T, Mori M. Rapid growth of malignant pleural mesothelioma. J Thorac Oncol 2007; 2:966 - 7; http://dx.doi.org/10.1097/JTO.0b013e31811f474e; PMID: 17909361
   PubMed Web of Science ®Google Scholar
• Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012; 75:360 - 7; http://dx.doi.org/10.1016/j.lungcan.2011.08.011; PMID: 21937142
   PubMed Web of Science ®Google Scholar
• Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010; 5:1655 - 61; http://dx.doi.org/10.1097/JTO.0b013e3181ec18db; PMID: 20736856
   PubMed Web of Science ®Google Scholar
• Fennell DA, McDowell CM, Busacca S, Webb G, Moulton B, Cakana A, O’Byrne KJ, Meerbeeck JV, Donnellan P, McCaffrey J, et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7:1466 - 70; http://dx.doi.org/10.1097/JTO.0b013e318260dfb9; PMID: 22895144
   PubMed Web of Science ®Google Scholar
• Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63:94 - 7; http://dx.doi.org/10.1016/j.lungcan.2008.04.001; PMID: 18486273
   PubMed Web of Science ®Google Scholar
• Nowak AK, Millward MJ, Creaney J, Francis RJ, Dick IM, Hasani A, van der Schaaf A, Segal A, Musk AW, Byrne MJ. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012; 7:1449 - 56; http://dx.doi.org/10.1097/JTO.0b013e31825f22ee; PMID: 22895142
   PubMed Web of Science ®Google Scholar
• Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 2012; 8:e1002594; http://dx.doi.org/10.1371/journal.ppat.1002594; PMID: 22438812
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875 - 86; http://dx.doi.org/10.1084/jem.20030152; PMID: 14676299
   PubMed Web of Science ®Google Scholar
• Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, Walker EB, Fox BA. Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol 2009; 183:3682 - 9; http://dx.doi.org/10.4049/jimmunol.0900560; PMID: 19692636
   PubMed Web of Science ®Google Scholar
• Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, Ferrari M, Cosentino M, Marino F, Pozzi E, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006; 67:1 - 12; http://dx.doi.org/10.1016/j.humimm.2005.11.005; PMID: 16698419
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412 - 20; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624; PMID: 19934295
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010; 15:969 - 75; http://dx.doi.org/10.1634/theoncologist.2010-0129; PMID: 20798195
   PubMed Web of Science ®Google Scholar
• Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60:433 - 42; http://dx.doi.org/10.1007/s00262-010-0960-8; PMID: 21221967
   PubMed Web of Science ®Google Scholar
• Sterman DH, Recio AR, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13:4456 - 66; http://dx.doi.org/10.1158/1078-0432.CCR-07-0403; PMID: 17671130
   PubMed Web of Science ®Google Scholar
• Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, Liu F, Brusic V, Neuberg D, Kutok JL, et al. Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res 2010; 70:1344 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-09-3143; PMID: 20124481
   PubMed Web of Science ®Google Scholar
• Fonseca C, Soiffer R, Ho V, Vanneman M, Jinushi M, Ritz J, Neuberg D, Stone R, DeAngelo D, Dranoff G. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood 2009; 113:1681 - 8; http://dx.doi.org/10.1182/blood-2007-09-114157; PMID: 19008459
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006; 13:555 - 62; http://dx.doi.org/10.1038/sj.cgt.7700922; PMID: 16410826
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yang JL, Price JO, Arteaga CL. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res 1998; 245:350 - 9; http://dx.doi.org/10.1006/excr.1998.4261; PMID: 9851876
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Kawano K, Minowa T, Sugino T, Shimojo Y, Maitani Y. Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-β type I receptor inhibitor. Cancer Sci 2010; 101:2207 - 13; http://dx.doi.org/10.1111/j.1349-7006.2010.01646.x; PMID: 20608940
   PubMed Web of Science ®Google Scholar
• Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, et al. Systemic blockade of transforming growth factor-β signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68:10247 - 56; http://dx.doi.org/10.1158/0008-5472.CAN-08-1494; PMID: 19074893
   PubMed Web of Science ®Google Scholar
• Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, et al. TGF-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid tumors. Clin Cancer Res 2008; 14:3966 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-08-0356; PMID: 18559619
   PubMed Web of Science ®Google Scholar
• Terabe M, Ambrosino E, Takaku S, O’Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15:6560 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-1066; PMID: 19861451
   PubMed Web of Science ®Google Scholar
• Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM, Berzofsky JA. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer 2010; 126:1666 - 74; PMID: 19830696
   PubMed Web of Science ®Google Scholar
• Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, Aranda F, Berraondo P, Prieto J, Lasarte JJ, et al. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009; 125:2614 - 23; http://dx.doi.org/10.1002/ijc.24656; PMID: 19530254
   PubMed Web of Science ®Google Scholar
• Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257 - 60; http://dx.doi.org/10.1093/annonc/mdh059; PMID: 14760119
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Ramanathan R, Yingling JM, Baselga J, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M. Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases. Biologics 2008; 2:563 - 9; PMID: 19707386
   PubMedGoogle Scholar